221 related articles for article (PubMed ID: 33929995)
1. Molecularly targeted therapy for advanced gastrointestinal noncolorectal cancer treatment: how to choose? Past, present, future.
Nigro O; Chini C; Proserpio I
Anticancer Drugs; 2021 Jun; 32(6):593-601. PubMed ID: 33929995
[TBL] [Abstract][Full Text] [Related]
2. The Role of Target Therapy in the Treatment of Gastrointestinal Noncolorectal Cancers: Clinical Impact and Cost Consideration.
Berretta M; Romano C; Di Francia R; De Diviitis C; Canzonieri V; Caraglia M; Facchini G; Nasti G
Curr Cancer Drug Targets; 2018; 18(5):430-441. PubMed ID: 28183250
[TBL] [Abstract][Full Text] [Related]
3. Current approaches to immunotherapy in noncolorectal gastrointestinal malignancies.
Jesus VHF; Felismino TC; Barros E Silva MJ; Souza E Silva V; Riechelmann RP
Clinics (Sao Paulo); 2018 Oct; 73(suppl 1):e510s. PubMed ID: 30365605
[TBL] [Abstract][Full Text] [Related]
4. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
5. Targeted therapies in gynecologic cancers.
Chon HS; Hu W; Kavanagh JJ
Curr Cancer Drug Targets; 2006 Jun; 6(4):333-63. PubMed ID: 16848724
[TBL] [Abstract][Full Text] [Related]
6. Role of biological targeted therapies in gastroenteropancreatic neuroendocrine tumours.
Yim KL
Endocrine; 2011 Oct; 40(2):181-6. PubMed ID: 21870172
[TBL] [Abstract][Full Text] [Related]
7. Unravelling the pharmacologic opportunities and future directions for targeted therapies in gastro-intestinal cancers Part 1: GI carcinomas.
Neuzillet C; Rousseau B; Kocher H; Bourget P; Tournigand C
Pharmacol Ther; 2017 Jun; 174():145-172. PubMed ID: 28223233
[TBL] [Abstract][Full Text] [Related]
8. Safety and Tolerability of Anti-Angiogenic Protein Kinase Inhibitors and Vascular-Disrupting Agents in Cancer: Focus on Gastrointestinal Malignancies.
Procaccio L; Damuzzo V; Di Sarra F; Russi A; Todino F; Dadduzio V; Bergamo F; Prete AA; Lonardi S; Prenen H; Palozzo AC; Loupakis F
Drug Saf; 2019 Feb; 42(2):159-179. PubMed ID: 30649744
[TBL] [Abstract][Full Text] [Related]
9. Rationale for the use of metronomic chemotherapy in gastrointestinal cancer.
Filippi R; Lombardi P; Depetris I; Fenocchio E; Quarà V; Chilà G; Aglietta M; Leone F
Expert Opin Pharmacother; 2018 Sep; 19(13):1451-1463. PubMed ID: 30161003
[TBL] [Abstract][Full Text] [Related]
10. Precision Medicine in Gastrointestinal Pathology.
Wang DH; Park JY
Arch Pathol Lab Med; 2016 May; 140(5):449-60. PubMed ID: 27128302
[TBL] [Abstract][Full Text] [Related]
11. Old Tyrosine Kinase Inhibitors and Newcomers in Gastrointestinal Cancer Treatment.
Giordani E; Zoratto F; Strudel M; Papa A; Rossi L; Minozzi M; Caruso D; Zaccarelli E; Verrico M; Tomao S
Curr Cancer Drug Targets; 2016; 16(2):175-85. PubMed ID: 26278713
[TBL] [Abstract][Full Text] [Related]
12. [Targeted therapy for locally advanced and/or metastatic bladder cancer].
Wallerand H; Robert G; Bernhard JC; Ravaud A; Ferrière JM
Prog Urol; 2008 Jul; 18(7):407-17. PubMed ID: 18602599
[TBL] [Abstract][Full Text] [Related]
13. Overcoming Resistance to Targeted Therapies in Gastrointestinal Cancers: Progress to Date and Progress to Come.
Chen C; Di Bartolomeo M; Corallo S; Strickler JH; Goyal L
Am Soc Clin Oncol Educ Book; 2020 May; 40():161-173. PubMed ID: 32421451
[TBL] [Abstract][Full Text] [Related]
14. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future.
Mulder K; Koski S; Scarfe A; Chu Q; King K; Spratlin J
Oncotarget; 2010 Nov; 1(7):515-529. PubMed ID: 21317448
[TBL] [Abstract][Full Text] [Related]
15. The future of Cochrane Neonatal.
Soll RF; Ovelman C; McGuire W
Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
[TBL] [Abstract][Full Text] [Related]
16. An update on biomarkers for kinase inhibitor response in non-small-cell lung cancer.
Ku BM; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Expert Rev Mol Diagn; 2017 Oct; 17(10):933-942. PubMed ID: 28838271
[TBL] [Abstract][Full Text] [Related]
17. Targeting the molecular pathophysiology of gastrointestinal stromal tumors with imatinib. Mechanisms, successes, and challenges to rational drug development.
Demetri GD
Hematol Oncol Clin North Am; 2002 Oct; 16(5):1115-24. PubMed ID: 12512386
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets in GI malignancies - A pathologist's perspective.
Pawar S; Sharma A
Indian J Pathol Microbiol; 2021 Jun; 64(Supplement):S43-S51. PubMed ID: 34135137
[TBL] [Abstract][Full Text] [Related]
19. New targeted agents in gastroenteropancreatic neuroendocrine tumors.
Benavent M; de Miguel MJ; Garcia-Carbonero R
Target Oncol; 2012 Jun; 7(2):99-106. PubMed ID: 22585431
[TBL] [Abstract][Full Text] [Related]
20. Molecularly targeted therapy for gastrointestinal cancer.
Wiedmann MW; Caca K
Curr Cancer Drug Targets; 2005 May; 5(3):171-93. PubMed ID: 15892618
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
